ERBB2 and breast cancer: Current clinical practice categorizes breast cancer into three subtypes based on immunohistochemistry (IHC) tests for estrogen receptor (ER), progesterone receptor (PR), and erythroblastic oncogene B/human epidermal growth factor receptor 2 (ErbB2/HER2) expression.